Conflicting views on the molecular structure of the cancer antigen CA125/MUC16

Disease Markers

Volumn 28, Issue 6, 2010, Pages 385-394

  Bouanene, Houda ^a,b   Miled, Abdelhédi ^a,b  

^a UNIVERSITY OF MONASTIR   (Tunisia)

^b FARHAT HACHED HOSPITAL   (Tunisia)

Author keywords

CA125 antigen; Glycosylation; MUC16

Indexed keywords

CA 125 ANTIGEN; MEMBRANE PROTEIN; MUC16 PROTEIN, HUMAN; TUMOR MARKER;

CHEMICAL STRUCTURE; CHEMISTRY; FEMALE; HUMAN; METABOLISM; OVARY TUMOR; PATHOLOGY; REVIEW;

CA-125 ANTIGEN; FEMALE; HUMANS; MEMBRANE PROTEINS; MOLECULAR STRUCTURE; OVARIAN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 78149484157     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.3233/DMA-2010-0719     Document Type: Review

References (75)

1. T. Maggino and A. Gadducci, Serum markers as prognostic factors in epithelial ovarian cancer: an overview, Eur J Gynaecol Oncol 21 (2000), 64-69.
2. G.J. Rustin, M. Marples, A.E. Nelstrop, M. Mahmoudi and T. Meyer, Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels, J Clin Oncol 19 (2001), 4054-4057.
3. D. Sok, L.J.A. Clarizia, L.R. Farris and M.J. McDonald, Novel fluoroimmunoassay for ovarian cancer biomarker CA-125, Analytical and bioanalytical chemistry 393 (2009) 1521-1523.
4. M.K. Tuxen, G. Soletormos, G.J.S. Rustin, A.E. Nelstrop and P. Dombernowsky, Biological variation and analytical imprecision of CA125 in patients with ovarian cancer, Scand J Clin Lab Investigation 60 (2000), 713-722.
5. B. Yu, P.Z. Xu, Q.W.Wang, H. Zhou and H.X. Zhou, Clinical value of tumour specific growth factor (TSGF) and carbohydrate antigen-125 (CA-125) in carcinoma of the endometrium, J Int Med Res 37 (2009), 878-883.
6. L.F. Norum, B. Erikstein and K. Nustad, Elevated CA125 in breast cancer - A sign of advanced disease, Tumor Biol 22 (2001), 223-228.
7. S. Homma, H. Satoh, K. Kagohashi, M. Fujiwara, H. Kamma and K. Sekizawa, Production of CA125 by human lung cancer cell lines, J Int Med Res 37 (2009), 878-883.
8. C. Miralles, M. Orea, P. Espana, M. Provencio, A. Sánchez, B. Cantos, R. Cubedo, E. Carcereny, F. Bonilla and T. Gea, Cancer antigen 125 associated with multiple benign and malignant pathologies, Ann Surg Oncol 10 (2003), 150-154.
9. M.R. McLemore and B. Aouizerat, Introducing the MUC16 Gene: Implications for Prevention and Early Detection in Epithelial Ovarian Cancer, Biological Res Nurs 6 (2005), 262-267.
10. Jr.R.C. Bast, M. Feeney, H. Lazarus, L.M. Nadler, R.B. Colvin and R.C. Knapp, Reactivity of a monoclonal antibody with human ovarian carcinoma, J Clin Investig 68 (1981), 1331-1337.
11. Jr.R.C. Bast, F.J. Xu, Y.H. Yu, S. Barnhill, Z. Zhang and G.B. Mills, CA 125: the past and the future, Int J Biol Markers 13 (1998), 179-187.
12. D.G. Rosen, L. Wang, J.N. Atkinson, Y. Yu, K.H. Lu, E.P. Diamandis, I. Hellstrom, S.C. Mok, J. Liu and R.C. Jr. Bast, Potential markers that complement expression of CA125 in epithelial ovarian cancer, Gynecol Oncol 99 (2005), 267-277.
13. N. Scholler, M. Crawford, A. Sato, C.W. Drescher, K.C. O’Briant, N. Kiviat, G.L. Anderson and N. Urban, Bead-based ELISA for validation of ovarian cancer early detection markers, Clin Cancer Res 12 (2006), 2117-2124.
14. R.G. Moore, A.K. Brown, M.C. Miller, S. Skates, W.J. Allard, T. Verch M. Steinhoff, G. Messerlian, P. DiSilvestro, C.O. Granai and R.C. Jr. Bast, The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass, Gynecol Oncol 108 (2008), 402-408.
15. Y. Zheng, D. Katsaros, S.J. Shan, I.R. De la Longrais, M. Porpiglia, A. Scorilas, N.W. Kim, R.L.Wolfert, I. Simon, L. Li, Z. Feng and E.P. Diamandis, A multiparametric panel for ovarian cancer diagnosis, prognosis, and response to chemotherapy, Clin Cancer Res 13 (2007), 6984-6992.
16. C. Crump, M.W. McIntosh, N. Urban, G. Anderson and B.Y. Karlan, Ovarian cancer tumor marker behavior in asymptomatic healthy women: Implications for screening, Cancer Epidemiol Biomarkers Prev 9 (2000), 1107-1111.
17. Z. Zhang, Jr.R.C. Bast, Y. Yu, J. Li, L.J. Sokoll and A.J. Rai, Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer, Cancer Res 64 (2004), 5882-5890.
18. K.L. Terry, P.M. Sluss, S.J. Skates, S.C. Mok, B. Ye, A.F. Vitonis and D.W. Cramer, Blood and urine markers for ovarian cancer: A comprehensive review, Dis Markers 20 (2004), 53-70.
19. R.C. Jr. Bast, D. Badgwell, Z. Lu, R. Marquez, D. Rosen, J. Liu, K.A. Baggerly, E.N. Atkinson, S. Skates, Z. Zhang, A. Lokshin, U. Menon, I. Jacobs and K. Lu, New tumor markers: CA125 and beyond, Int J Gynecol Cancer 15 (2005), 274-281.
20. N. Kothandaraman, C. Zhao and C. Mahesh, Ovarian cancer proteomics: Many technologies one goal, Proteomics Clin Appl 2 (2008), 195-218.
21. A.J. Rai, A.J. Zhang, Z. Rosenzweig, J. Shih, L. Pham, T. Fung, J. Lori, L.J. Sokoll and D.W. Chan, Proteomic Approaches to Tumor Marker Discovery Identification of Biomarkers for Ovarian Cancer, Arch Pathol Lab Med 126 (2002), 1518-1526.
22. R.C. Jr. Bast, T.L. Klug, E. St John, E. Jenison, J.M. Niloff, H. Lazarus, R.S. Berkowitz, T. Leavitt, C.T. Griffiths, L. Parker, V.R. Zurawski and Jr.R.C. Knapp, A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer, N Engl J Med 309 (1983), 883-887.
23. K. Nustad, R.C. Jr. Bast, T.J. Brien, O. Nilsson, P. Seguin, M.R. Suresh, T. Saga, S. Nozawa, O.P. Bormer, H.W. de Bruijn, M. Nap, A. Vitali, M. Gadnell, J. Clark, K. Shigemasa, B. Karlsson, F.T. Kreutz, D. Jette, H. Sakahara, K. Endo, E. Paus, D. Warren, S. Hammarstrom, P. Kenemans and J. Hilgers, Specificity and affinity of 26 monoclonal antibodies against the CA125 antigen: first report from the ISOBM TD-1 workshop International Society for Oncodevelopmental Biology and Medicine, Tumor Biol 17 (1996), 196-219.
24. K. Tamakoshi, F. Kikkawa, N. Hasegawa, H. Ishikawa, K. Mizuno, M. Kawai and Y. Tomoda, Clinical value of a new serum tumor marker, CA125II, in gynecologic disease: comparison with CA125, Gynecol Obstet Investig 39 (1995), 125-129.
25. E.M. Davelaar, G.J. Van Kamp, R.A. Verstraeten and P. Kenemans, Comparison of seven immunoassays for the quantification of CA 125 antigen in serum, Clin Chem 44 (1998), 1417-1422.
26. O. Mogensen and B. Mogensen, Measurement of CA 125 by an automated microparticle enzyme immunoassay; comparison with a manual enzyme immunoassay, Scan J Clin Lab Invest 52 (1992), 507-512.
27. K. Nustad, Y. Lebedin, K.O. Lloyd, K. Shigemasa, H.W.A. de Bruijn, B. Jansson, O. Nilsson, K.H. Olsen and T.J. O’Brien, Epitopes on CA125 from Cervical Mucus and Ascites Fluid and Characterization of Six New Antibodies, Tumor Biol 23 (2002), 303-314.
28. F. Paulsen, Cell and molecular biology of human lacrimal gland and nasolacrimal duct mucins, Int Rev Cytol 249 (2006), 229-279.
29. F. Paulsen and M. Berry, Mucins and TFF peptides of the tear film and lacrimal apparatus, Prog Histochem Cytochem 41 (2006), 1-56.
30. T. Blalock, S. Spurr-Michaud, A. Tisdale, S. Heimer, M. Gilmore, V. Ramesh and I.K. Gipson, Functions of MUC16 in corneal epithelial cells, Invest Ophthalmol Vis Sci 48 (2007), 4509-4518.
31. P. Argeso, S. Spurr-Michaud, C.L. Russo, A. Tisdale and I.K. Gipson, MUC16 mucin is expressed by the human ocular surface epithelia and carries the H185 carbohydrate epitope, Invest Ophthalmol Vis Sci 44 (2003), 2487-2495.
32. K. Jäger, G. Wu, S. Sel, F. Garreis, L. Bräuer and F. Paulsen, Detection and distribution of MUC16 in the lacrimal apparatus, Histochem Cell Biol 127 (2006), 433-438.
33. S. Spurr-Michaud, P. Argeso and I.K. Gipson, Assay of mucins in human tear fluid, Exp Eye Res 84 (2007), 939-950.
34. F. Paulsen, K. Jäger, D. Worlitzschb, L. Bräuera, U. Schulzea and G. Schäferc, Regulation of, MUC16 by inflammatory mediators in ocular surface epithelial cell lines, Ann Anatomy 190 (2008), 59-70.
35. C. Seelenmeyer, S. Wegehingel, J. Lechner and W. Nickel, The cancer antigen CA125 represents a novel counter receptor for galectin-1, J Cell Sc 116 (2003), 1305-1318.
36. A. Rump, Y. Morikawa, M. Tanaka, S. Minami, N. Umesaki, M. Takeuchi and A. Miyajima, Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion, J Biol Chem 279 (2004), 9190-9198.
37. J.A.Gubbels, J. Belisle, M. Onda, C. Rancourt, M. Migneault, M. Ho, T.K. Bera, J. Connor, B.K. Sathyanarayana, B. Lee, I. Pastan and M.S. Patankar, Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors, Mol Cancer 5 (2006), 50.
38. G.A. Rabinovich, N. Rubinstein and L. Fainboim, Unlock the secrets of galectins: a challenge at the frontier of the glycoimmunology, J Leukocyte Biol 71 (2002), 741-752.
39. O. Kaneko, L. Gong, J. Zhang, J.K. Hansen, R. Hassan, B. Lee and M. Ho, A Binding Domain on Mesothelin for CA125/MUC16, J Biol Chem 284 (2009), 3739-3749.
40. K. Nustad, M. Onsrud, B. Jansson and D. Warren, CA125- epitopes and molecular size, Int J Biol Markers 134 (1998), 196-199.
41. F.G. Hanisch, G. Uhlenbruck, C. Dienst, M. Stottrop and E. Hippauf, CA125 and CA 19-9: two cancer-associated sialylsaccharide antigens on a mucus glycoprotein from human milk, Eur J Biochem 149 (1985), 323-330.
42. T.J. O’Brien, J.B. Beard, L.J. Underwood, R.A. Dennis, A.D. Santin and L. York, The CA125 gene: an extracellular superstructure dominated by repeat sequences, Tumor Biol 22 (2001), 348-366.
43. H.M. Davis, V.R. Jr. Zurawski, R.C. Jr. Bast and T.L. Klug, Characterization of the CA125 antigen associated with human epithelial ovarian carcinoma, Cancer Res 46 (1986), 6143-6148.
44. Y.H. Yu, D.M. Schlossman, C.L. Harrison, A. Rhinehardt-Clark, J.T. Soper, T.L. Klug, V.R. Zurawski and R.C. Jr. Bast, Coexpression of Different Antigenic Markers on Moieties That Bear CA 125 Determinants, Cancer Res 51 (1991), 468-475.
45. M.T. De los Frailes, S. Stark, W. Jaeger, A. Hoerauf and L. Wildt, Purification and characterization of the CA 125 tumorassociated antigen from human ascites, Tumor Biol 14 (1993), 18-29.
46. A. Barbati, Immunoblotting characterization of CA 125 in biological fluids: difference between pregnancy and cancer CA 125 origin, Anticancer Res 166B (1996), 3621-3624.
47. H.W. De Bruijn, C. Van-Beeck-Calkoen, S. Jager, J.M. Duk, J.G. Aalders and G.J. Fleuren, The tumor marker CA125 is a common constituent of normal cervical mucus, Am J Obstet Gynecol 154 (1986), 1088-1091.
48. B. Macao, D.G.A. Johansson, G.C. Hansson and T. Härd, Auto-proteolysis coupled to protein folding in the SEAdomain of the membrane-bound MUC1 mucin, Nat Struct Mol Biol 13 (2006), 71-76.
49. T.J. O’Brien, H. Tanimoto, I. Konishi and M. Gee, More than 15 years of CA125: what is known about the antigen, its structure and its function, Int J Biol Markers 13 (1998), 188-195.
50. M.R. McLemore and B. Aouizerat, Introducing the MUC16 Gene: Implications for Prevention and Early Detection in Epithelial Ovarian Cancer, Biol Res Nur 6 (2005), 262-267.
51. K.O. Lloyd, B.W.T. Yin and V. Kudryashov, Isolation and characterization of ovarian cancer antigen CA 125 using a new monoclonal antibody VK-8: identification as a mucin - type molecule, Int J Cancer 71 (1997), 842-850.
52. A. Gottschalk and A.S. Bhargava, Submaxillary gland glycoproteins. In: Glycoproteins, A. Gottschalk, ed., Part B, 1972, 810-829.
53. K.O. Lloyd, Glycoproteins with blood group activity, In: International Review of Science, G.O. Aspinall, ed., Organic Chemistry 7 (1976), 252-281.
54. W.J. Murdoch, E.A. Van Kirk and A.Mc. Smedts, Complement-inhibiting effect of ovarian cancer antigen CA-125, Cancer Lett 236 (2006), 54-57.
55. B.C. Schultes, R.P. Baum, A. Niesen, A.A. Noujaim and R. Madiyalakan, Anti-idiotype induction therapy: anti-CA125 antibodies (Ab3) mediated tumor killing in patients treated with ovarex mAb B43.13 (Ab1) Cancer Immunol Immunother 46 (1998), 201-212.
56. K.O. Lloyd and B.W.T.Yin, Synthesis and secretion of the ov arian cancer antigen CA125 by the human cancer cell line NIH: OVCAR-3, Tumor Biol 222 (2001), 77-82.
57. S. Imai, H. Maeda, Y. Kiyozuka, T. Noda, I. Moriyama and M. Ichijo, Characterization of the CA125 antigen secreted from a newly established human ovarian cancer cell line (SHIN-3), Acta Pathol Jpn 39 (1989), 43-49.
58. B.W.T. Yin and K.O. Lloyd, Molecular cloning of the CA125 ovarian cancer antigen, J Biol Chem 276 (2001), 27371-27375.
59. E. Levi, D.S. Klimstra, N.V. Adsay, A. Andea and O. Basturk, MUC1 and MUC2 in pancreatic neoplasia, J Clin Pathol 57 (2004), 456-462.
60. L.E. Vinall, S. Hilla, P. Pigny, W.S. Pratt, N. Toribara, J.R. Gum, Y.S. Kim, N. Porchet, J.P. Aubert and D.M. Swallow, Variable number tandem repeat polymorphism of the mucin genes located in the complex on 11p15.5, Hum Genet 102 (1998), 357-366.
61. J.L. Desseyn, D. Tetaert and V. Gouyer, Architecture of the large membrane-bound mucins, Gene 410 (2008), 215-222.
62. T. Maeda, M. Inoue, S. Koshiba, T. Yabuki, M. Aoki and E. Nunokawa, Solution structure of the SEA domain from the murine homologue of ovarian cancer antigen CA125 (MUC16), J Biol Chem 279 (2003), 13174-13182.
63. T.J. O’Brien, J.B. Beard and L.J. Underwood, The CA 125 gene: A newly discovered extension of the glycosylated Nterminal domain doubles the size of this extracellular superstructure, Tumor Biol 23 (2002), 154-169.
64. E.J. Nouwen, S. Dauwe and M.E. De Broe, Occurrence of the mucinous differentiation antigen CA125 in genital tract and conductive airway epithelia of diverse mammalian species (rabbit, dog, monkey), Differentiation 45 (1990), 192-198.
65. A.C. McDonnel, E.A. Van Kirk, K.J. Austin, T.R. Hansen, E.L. Belden and W.J. Murdoch, Expression of CA-125 by progestational bovine endometrium: prospective regulation and function, Reproduction 126 (2003), 615-620.
66. N. Scholler, B. Garvik, M. Hayden-Ledbetter, T. Kline and N. Urban, Development of a CA125-mesothelin cell adhesion assay as a screening tool for biologics discovery, Cancer Lett 247 (2007), 130-136.
67. J.L. Fendrick, I. Konishi, S.M. Geary, T.H. Parmley, J.G. Jr. Quirk and T.J. O’Brien, CA125 phosphorylation is associated with its secretion from the WISH human amnion cell line, Tumor Biol 18 (1997), 278-289.
68. N.K. Wong, R.L. Easton, M. Panico, M. Sutton-Smit, J.C. Morrison, F.A. Lattanzio, H.R. Morris, G.F. Clark, A. Dell and M.S. Patankar, Characterization of the Oligosaccharides Associated with the Human Ovarian Tumor Marker CA125, J Biol Chem 278 (2003), 28619-28634.
69. A. Nagata, N. Hirota, T. Sakai, M. Fujimoto and T. Komoda, Molecular nature and possible presence of a membranous glycan-phosphatidylinositol anchor of CA125 antigen, Tumor Biol 12 (1991), 279-286.
70. M.M. Jankovic and B.S. Tapuskovic, Molecular forms and microheterogeneity of the oligosaccharide chains of pregnancyassociated CA125 antigen, Hum Reprod 20 (2005), 2632-2638.
71. M.M. Jankovic and B.S. Milutinovic, Glycoforms of CA125 antigen as a possible cancer marker, Cancer Biomark 4 (2008), 35-42.
72. B. Milutinovic and M. Jankovic, Analysis of the protein and glycan parts of CA125 antigen from human amniotic fluid, Arch Biol Sci 59 (2007), 97-103.
73. J.R. Davies, S. Kirkham, N. Svitacheva, D.J. Thornton, I. Carlstedt, MUC16 is produced in tracheal surface epithelium and submucosal glands and is present in secretions from normal human airway and cultured bronchial epithelial cells, Int J Biochem Cell B 39 (2007), 1943-1954.
74. Y. Andersch-Bjorkman, K.A. Thomsson, J.M. Holmeʼn Larsson, E. Ekerhovd and G.C. Hansson, Large Scale Identification of Proteins, Mucins, and Their O-Glycosylation in the Endocervical Mucus during the Menstrual Cycle, Mol Cell Proteomics 6 (2007), 708-716.
75. D.J. States, G.S. Omenn, T.W. Blackwell, D. Fermin, J. Eng, D.W. Speicher and S.M. Hanash, Challenges in derinving high-confidence protein identification from data gathered by a HUPO plasma proteome collaborative study, Nat Biotechnol 24 (2006), 333-338.